<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996332</url>
  </required_header>
  <id_info>
    <org_study_id>ML17915</org_study_id>
    <nct_id>NCT01996332</nct_id>
  </id_info>
  <brief_title>A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>An Open-label Study of the Effect of Tarceva Monotherapy on Treatment Response in Patients With Advanced Non-small Cell Lung Cancer for Whom Tarceva Monotherapy is Considered the Best Option</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of oral Tarceva in patients with advanced
      NSCLC for whom Tarceva monotherapy is considered the best therapeutic option. The anticipated
      time on study treatment is 3-12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Disease Progression or Death by Line of Treatment</measure>
    <time_frame>Baseline, every 6-8 weeks up to 3 years until disease progression or death</time_frame>
    <description>Time to progression or death was defined as the time from inclusion to the date of disease progression or death, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Benefit by Line of Treatment</measure>
    <time_frame>Baseline, every 6-8 weeks up to 3 years or until death</time_frame>
    <description>Efficacy was analyzed in terms of clinical benefit, defined as the sum of the number of participants achieving complete response [CR], partial response [PR], or stable disease [SD]. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. CR was defined as disappearance of all target and non-target lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) by Line of Treatment</measure>
    <time_frame>Baseline, every 6-8 weeks up to 3 years, or until death</time_frame>
    <description>Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date or last known alive date [if death date was unavailable] minus the date of first dose of study medication plus 1 divided by 30.44).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1805</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Tarceva Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib [Tarceva]</intervention_name>
    <description>150 mg/day until progressive disease or unacceptable toxicity</description>
    <arm_group_label>Tarceva Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients &gt;=18 years of age;

          -  locally advanced or metastatic NSCLC (Stage IIIB or IV);

          -  not a candidate for curative surgery or radical chemotherapy;

          -  no brain metastases, or clinically stable metastases for &gt;=2 months.

        Exclusion Criteria:

          -  radiotherapy over the previous 2 weeks;

          -  weight loss &gt;10% in the previous 6 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Alcoy</city>
        <state>Alicante</state>
        <zip>03804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almería</city>
        <state>Almeria</state>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Don Benito</city>
        <state>Badajoz</state>
        <zip>06400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <state>Badajoz</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mataro</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell, Barcelona</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sant Coloma Gramenet</city>
        <state>Barcelona</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sant Pere de Ribes</city>
        <state>Barcelona</state>
        <zip>08810</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>VIC</city>
        <state>Barcelona</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Algeciras</city>
        <state>Cadiz</state>
        <zip>11207</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cádiz</city>
        <state>Cadiz</state>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerez de La Frontera</city>
        <state>Cadiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puerto Real</city>
        <state>Cadiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrevieja</city>
        <state>Cantabria</state>
        <zip>03180</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baza</city>
        <state>Granada</state>
        <zip>18800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibiza</city>
        <state>Islas Baleares</state>
        <zip>07800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrol</city>
        <state>La Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruna</city>
        <state>La Coruña</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avila</city>
        <zip>05071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Castellon</city>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <zip>18003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lerida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palencia</city>
        <zip>34005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <zip>47010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <results_first_submitted>June 9, 2014</results_first_submitted>
  <results_first_submitted_qc>June 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 10, 2014</results_first_posted>
  <last_update_submitted>June 9, 2014</last_update_submitted>
  <last_update_submitted_qc>June 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three cohorts were established in participants with advanced non-small cell lung cancer (NSCLC) based on previous chemotherapy treatment received: first line of treatment (where conventional chemotherapy is not indicated), second line of treatment, and third and subsequent lines of treatment. Inclusion was competitive.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib 150 Milligrams Per Day (mg/Day)</title>
          <description>Participants received erlotinib 150 milligrams/day (mg/day), orally, until progressive disease or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1805"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1805"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1245"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="264"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Deterioration</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population defined as all participants included to each of three cohorts based on prior chemotherapy treatment received: first-line monotherapy (for whom conventional chemotherapy was not indicated), second-line monotherapy, and third or subsequent lines of treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib 150 mg/Day</title>
          <description>Participants received erlotinib 150 mg/day, orally, until progressive disease or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1805"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.55" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Disease Progression or Death by Line of Treatment</title>
        <description>Time to progression or death was defined as the time from inclusion to the date of disease progression or death, whichever occurred first.</description>
        <time_frame>Baseline, every 6-8 weeks up to 3 years until disease progression or death</time_frame>
        <population>ITT Population; data were analyzed in 6 cohorts, with erlotinib treatment as: 1) first line; 2) maintenance after first line; 3) second line; 4) maintenance after second line; 5) third or subsequent line; or 6) maintenance after third line</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib 150 mg/Day</title>
            <description>Participants received erlotinib 150 mg/day, orally, until progressive disease or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression or Death by Line of Treatment</title>
          <description>Time to progression or death was defined as the time from inclusion to the date of disease progression or death, whichever occurred first.</description>
          <population>ITT Population; data were analyzed in 6 cohorts, with erlotinib treatment as: 1) first line; 2) maintenance after first line; 3) second line; 4) maintenance after second line; 5) third or subsequent line; or 6) maintenance after third line</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1805"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.9" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance after 1st Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.5" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance after 2nd Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.2" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd or Subsequent Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="2.2" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance after 3rd Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.8" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Benefit by Line of Treatment</title>
        <description>Efficacy was analyzed in terms of clinical benefit, defined as the sum of the number of participants achieving complete response [CR], partial response [PR], or stable disease [SD]. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. CR was defined as disappearance of all target and non-target lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non target lesions.</description>
        <time_frame>Baseline, every 6-8 weeks up to 3 years or until death</time_frame>
        <population>Response evaluable population: participants with measurable disease and with matching criteria to have a response assessment; data were analyzed in 6 cohorts, with erlotinib treatment as: 1) first line; 2) maintenance after first line; 3) second line; 4) maintenance after second line; 5) third or subsequent line; or 6) maintenance after third line</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib 150 mg/Day</title>
            <description>Participants received erlotinib 150 mg/day, orally, until progressive disease or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Benefit by Line of Treatment</title>
          <description>Efficacy was analyzed in terms of clinical benefit, defined as the sum of the number of participants achieving complete response [CR], partial response [PR], or stable disease [SD]. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. CR was defined as disappearance of all target and non-target lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non target lesions.</description>
          <population>Response evaluable population: participants with measurable disease and with matching criteria to have a response assessment; data were analyzed in 6 cohorts, with erlotinib treatment as: 1) first line; 2) maintenance after first line; 3) second line; 4) maintenance after second line; 5) third or subsequent line; or 6) maintenance after third line</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.32" lower_limit="65.21" upper_limit="75.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance treatment after 1st line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.00" lower_limit="53.47" upper_limit="83.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.04" lower_limit="53.39" upper_limit="62.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance treatment after 2nd line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.68" lower_limit="48.80" upper_limit="90.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd or subsequent line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.71" lower_limit="47.61" upper_limit="57.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance treatment after 3rd line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" lower_limit="15.70" upper_limit="84.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) by Line of Treatment</title>
        <description>Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date or last known alive date [if death date was unavailable] minus the date of first dose of study medication plus 1 divided by 30.44).</description>
        <time_frame>Baseline, every 6-8 weeks up to 3 years, or until death</time_frame>
        <population>ITT Population; data were analyzed in 6 cohorts, with erlotinib treatment as: 1) first line; 2) maintenance after first line; 3) second line; 4) maintenance after second line; 5) third or subsequent line; or 6) maintenance after third line</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib 150 mg/Day</title>
            <description>Participants received erlotinib 150 mg/day, orally, until progressive disease or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) by Line of Treatment</title>
          <description>Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date or last known alive date [if death date was unavailable] minus the date of first dose of study medication plus 1 divided by 30.44).</description>
          <population>ITT Population; data were analyzed in 6 cohorts, with erlotinib treatment as: 1) first line; 2) maintenance after first line; 3) second line; 4) maintenance after second line; 5) third or subsequent line; or 6) maintenance after third line</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1805"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.8" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sequential treatment after 1st line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="6.2" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="5.2" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sequential treatment after 2nd line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="2.2" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Line or subsequent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="4.3" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sequential treatment after 3rd line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.0" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the administration of first dose of study medication to the end of study or until death.</time_frame>
      <desc>Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib 150 mg/Day</title>
          <description>Participants received erlotinib 150 mg/day, orally, until progressive disease or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI v3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="566" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobbin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Gastrointestinal/other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Ileus GI</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Obstruction/GU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - abdominal NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Obstruction/GI</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms/other</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Edema Limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Uncoded</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Gallbladder infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - blood</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - brain (encephalitis, infectious)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - bronchus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - catheter - related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - soft tissue NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - upper aerodigestive NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Infection - wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Syndromes/other-superior cava vein</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - chest wall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - muscle</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Involuntary movement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Neuropathy/motor</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Neuropathy/sensory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - neuralgia/peripheral nerve</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Mood alteration - agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Neurology/other</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pain - pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Airway obstruction/upper respiratory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pulmonary/obstruction/stenosis of airway (bronchus)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Pulmonary/others</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Tracheal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Dermatology/skin - other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Drug abuser</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Opioid abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intraoperative complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1805"/>
              </event>
              <event>
                <sub_title>Vascular/other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1805"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI v3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1695" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Watery eye</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - eye</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="631" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Gastrointestinal/other</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Incontinence, anal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Ileus GI</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Obstruction/GU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hemorrhage/GI</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - abdomen nos</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - dental/teeth/peridontal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Obstruction/GI</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="650" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms/other</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hemorrhage/other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Edema head and neck</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Lymphatic/other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Gait</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain nos</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - face</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Syndromes/other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Uncoded</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hepatic cysts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - liver</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - ungual (nail)</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - urinary tract nos</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - bronchus</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - eye nos</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - soft tissue nos</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - upper aerodigestive nos</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - pharynx</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - blood</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - lip/perioral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - upper airway nos</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - vagina</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - auditory ear</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Gallbladder infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - brain (encephalitis, infectious)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - sinus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - bone (osteomyelitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - salivary gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - dental-tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - catheter-related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Infection - vulva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Syndromes/other-superior cava vein</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Leucocytes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Band neutrophil percentage increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>ADH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>GGT</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>CPK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="462" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Metabolic lab/other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/other</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - chest wall</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - muscle</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - joint</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - bone</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - limb</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - neck</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain - tumor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal episodes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Taste Alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Neuropathy/sensory</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Neurology/other</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Neuropathy/motor</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Involuntary movement</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Neuropathy cranial</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - headache</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - neuralgia/peripheral nerve</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Mood alteration-anxiety</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Mood alteration-agitation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression-anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/GU</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - Kidney</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Renal/other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Urine colour change</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual/reproductive function</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - pleura</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="691" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="436" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pulmonary/other</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pulmonary/obstruction/stenosis of airway (bronchus)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Chest tube drainage or leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Trachael fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Airway obstruction/upper respiratory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="897" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dermatology/skin-other</sub_title>
                <counts group_id="E1" subjects_affected="307" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hand foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pain - scalp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Opioid abuse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Drug abuser</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intraoperative complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Vascular/other</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1797"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1797"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann- LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

